Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.

Idowu T, Ammeter D, Rossong H, Zhanel GG, Schweizer F.

J Med Chem. 2019 Oct 9. doi: 10.1021/acs.jmedchem.9b00876. [Epub ahead of print]

PMID:
31557020
2.

Vaccine strategies for prevention of community-acquired pneumonia in Canada: Who would benefit most from pneumococcal immunization?

Kaplan A, Arsenault P, Aw B, Brown V, Fox G, Grossman R, Jadavji T, Laferrière C, Levitz S, Loeb M, McIvor A, Mody CH, Poulin Y, Shapiro M, Tessier D, Théorêt F, Weiss K, Yaremko J, Zhanel G.

Can Fam Physician. 2019 Sep;65(9):625-633. Review.

3.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Lagacé-Wiens PRS, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Golding G, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv22-iv31. doi: 10.1093/jac/dkz284.

PMID:
31505648
4.

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv64-iv71. doi: 10.1093/jac/dkz289.

PMID:
31505647
5.

Characterization of MRSA in Canada from 2007 to 2016.

Nichol KA, Adam HJ, Golding GR, Lagacé-Wiens PRS, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv55-iv63. doi: 10.1093/jac/dkz288.

PMID:
31505646
6.

Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011-16 study.

Fuller J, Dingle TC, Bull A, Shokoples S, Laverdière M, Baxter MR, Adam HJ, Karlowsky JA, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv48-iv54. doi: 10.1093/jac/dkz287.

PMID:
31505645
7.

Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.

Golden AR, Baxter MR, Davidson RJ, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG, Adam HJ; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv39-iv47. doi: 10.1093/jac/dkz286.

PMID:
31505644
8.

Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.

McCracken MG, Adam HJ, Blondeau JM, Walkty AJ, Karlowsky JA, Hoban DJ, Zhanel GG, Mulvey MR; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv32-iv38. doi: 10.1093/jac/dkz285.

PMID:
31505643
9.

Ten years of the CANWARD Study (2007-16).

Zhanel GG, Adam HJ; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv2-iv4. doi: 10.1093/jac/dkz282. No abstract available.

PMID:
31505642
10.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Golden AR, Hink R, Lagacé-Wiens PRS, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv5-iv21. doi: 10.1093/jac/dkz283.

PMID:
31505641
11.

Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate β-lactam antibiotics against multidrug-resistant P. aeruginosa.

Ammeter D, Idowu T, Zhanel GG, Schweizer F.

J Antibiot (Tokyo). 2019 Nov;72(11):816-826. doi: 10.1038/s41429-019-0221-9. Epub 2019 Aug 16.

PMID:
31420586
12.

Microbiology and Preclinical Review of Omadacycline.

Karlowsky JA, Steenbergen J, Zhanel GG.

Clin Infect Dis. 2019 Aug 1;69(Supplement_1):S6-S15. doi: 10.1093/cid/ciz395.

13.

Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anticancer Drug Mitomycin C Against Multidrug-Resistant Gram-Negative Bacteria.

Domalaon R, Ammeter D, Brizuela M, Gorityala BK, Zhanel GG, Schweizer F.

Front Microbiol. 2019 Jul 10;10:1556. doi: 10.3389/fmicb.2019.01556. eCollection 2019.

14.

Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.

Idowu T, Ammeter D, Arthur G, Zhanel GG, Schweizer F.

J Antimicrob Chemother. 2019 Sep 1;74(9):2640-2648. doi: 10.1093/jac/dkz228.

PMID:
31139830
15.

Amphiphilic nebramine-based hybrids Rescue legacy antibiotics from intrinsic resistance in multidrug-resistant Gram-negative bacilli.

Yang X, Ammeter D, Idowu T, Domalaon R, Brizuela M, Okunnu O, Bi L, Guerrero YA, Zhanel GG, Kumar A, Schweizer F.

Eur J Med Chem. 2019 Aug 1;175:187-200. doi: 10.1016/j.ejmech.2019.05.003. Epub 2019 May 2.

PMID:
31078866
16.

Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.

Berry L, Domalaon R, Brizuela M, Zhanel GG, Schweizer F.

Medchemcomm. 2019 Mar 7;10(4):517-527. doi: 10.1039/c9md00051h. eCollection 2019 Apr 1.

PMID:
31057731
17.

In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.

Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, Zhanel GG.

Int J Antimicrob Agents. 2019 Jul;54(1):62-68. doi: 10.1016/j.ijantimicag.2019.04.012. Epub 2019 Apr 26.

PMID:
31034938
18.

Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli.

Domalaon R, Okunnu O, Zhanel GG, Schweizer F.

J Antibiot (Tokyo). 2019 Aug;72(8):605-616. doi: 10.1038/s41429-019-0186-8. Epub 2019 Apr 26.

PMID:
31028351
19.

Heterodimeric Rifampicin-Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model.

Idowu T, Arthur G, Zhanel GG, Schweizer F.

Eur J Med Chem. 2019 Jul 15;174:16-32. doi: 10.1016/j.ejmech.2019.04.034. Epub 2019 Apr 16.

PMID:
31022550
20.

The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli.

Domalaon R, De Silva PM, Kumar A, Zhanel GG, Schweizer F.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02574-18. doi: 10.1128/AAC.02574-18. Print 2019 Apr.

21.

Identification of a novel metallo-β-lactamase, CAM-1, in clinical Pseudomonas aeruginosa isolates from Canada.

Boyd DA, Lisboa LF, Rennie R, Zhanel GG, Dingle TC, Mulvey MR.

J Antimicrob Chemother. 2019 Jun 1;74(6):1563-1567. doi: 10.1093/jac/dkz066.

PMID:
30789204
22.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Review.

PMID:
30712199
23.

Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017).

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):199-201. doi: 10.1016/j.diagmicrobio.2018.12.005. Epub 2018 Dec 14.

PMID:
30638654
24.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

PMID:
30500898
25.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

26.

Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.

Zhanel G, Critchley I, Lin LY, Alvandi N.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. doi: 10.1128/AAC.01297-18. Print 2019 Jan.

27.

Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria.

Domalaon R, Brizuela M, Eisner B, Findlay B, Zhanel GG, Schweizer F.

Amino Acids. 2019 Mar;51(3):383-393. doi: 10.1007/s00726-018-2673-9. Epub 2018 Nov 3.

PMID:
30392097
28.

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study.

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e02068-18. doi: 10.1128/AAC.02068-18. Print 2019 Jan.

29.

Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.

Domalaon R, Berry L, Tays Q, Zhanel GG, Schweizer F.

Bioorg Chem. 2018 Oct;80:639-648. doi: 10.1016/j.bioorg.2018.07.018. Epub 2018 Jul 19.

PMID:
30053708
30.

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.

Zhanel GG, Zhanel MA, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2018 Jun 25;2018:8912039. doi: 10.1155/2018/8912039. eCollection 2018. Review.

31.

Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, Levett PN, Zahariadis G, Haldane D, Gad R, German G, Gilmour MW, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii20-vii31. doi: 10.1093/jac/dky157.

PMID:
29982573
32.

Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii12-vii19. doi: 10.1093/jac/dky158.

PMID:
29982572
33.
34.

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii5-vii11. doi: 10.1093/jac/dky156.

PMID:
29982570
35.

Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016.

Demczuk WHB, Martin I, Desai S, Griffith A, Caron-Poulin L, Lefebvre B, McGeer A, Tyrrell GJ, Zhanel GG, Gubbay J, Hoang L, Levett PN, Van Caeseele P, Raafat Gad R, Haldane D, Zahariadis G, German G, Daley Bernier J, Strudwick L, Mulvey MR.

Vaccine. 2018 Jul 25;36(31):4701-4707. doi: 10.1016/j.vaccine.2018.06.018. Epub 2018 Jun 21.

PMID:
29937245
36.

Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa.

Yang X, Domalaon R, Lyu Y, Zhanel GG, Schweizer F.

J Clin Med. 2018 Jun 22;7(7). pii: E158. doi: 10.3390/jcm7070158.

37.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

PMID:
29748749
38.

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.

Zhanel GG, Zhanel MA, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2018 Jan 30;2018:1404813. doi: 10.1155/2018/1404813. eCollection 2018. Review.

39.

Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis.

Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G.

J Antimicrob Chemother. 2018 Jul 1;73(7):1888-1894. doi: 10.1093/jac/dky120.

PMID:
29635472
40.

Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Domalaon R, Idowu T, Zhanel GG, Schweizer F.

Clin Microbiol Rev. 2018 Mar 14;31(2). pii: e00077-17. doi: 10.1128/CMR.00077-17. Print 2018 Apr. Review.

41.

PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.

Karlowsky JA, Adam HJ, Kosowan T, Baxter MR, Nichol KA, Laing NM, Golding G, Zhanel GG.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):105-111. doi: 10.1016/j.diagmicrobio.2018.01.017. Epub 2018 Jan 31.

PMID:
29456070
42.

Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa.

Domalaon R, Sanchak Y, Koskei LC, Lyu Y, Zhanel GG, Arthur G, Schweizer F.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02374-17. doi: 10.1128/AAC.02374-17. Print 2018 Apr.

43.

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.

Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA.

Diagn Microbiol Infect Dis. 2018 May;91(1):55-62. doi: 10.1016/j.diagmicrobio.2017.12.013. Epub 2017 Dec 22.

PMID:
29338931
44.

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.

Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2018 Mar 1;73(3):703-708. doi: 10.1093/jac/dkx468.

PMID:
29244121
45.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:.

PMID:
29230684
46.

Biocide Selective TolC-Independent Efflux Pumps in Enterobacteriaceae.

Slipski CJ, Zhanel GG, Bay DC.

J Membr Biol. 2018 Feb;251(1):15-33. doi: 10.1007/s00232-017-9992-8. Epub 2017 Oct 23.

47.

Polymyxin B3-Tobramycin Hybrids with Pseudomonas aeruginosa-Selective Antibacterial Activity and Strong Potentiation of Rifampicin, Minocycline, and Vancomycin.

Domalaon R, Yang X, Lyu Y, Zhanel GG, Schweizer F.

ACS Infect Dis. 2017 Dec 8;3(12):941-954. doi: 10.1021/acsinfecdis.7b00145. Epub 2017 Oct 27.

PMID:
29045123
48.

Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy.

Lynch JP 3rd, Zhanel GG, Clark NM.

Semin Respir Crit Care Med. 2017 Jun;38(3):326-345. doi: 10.1055/s-0037-1602583. Epub 2017 Jun 4. Review.

PMID:
28578556
49.

Infections Due to Acinetobacter baumannii in the ICU: Treatment Options.

Lynch JP 3rd, Zhanel GG, Clark NM.

Semin Respir Crit Care Med. 2017 Jun;38(3):311-325. doi: 10.1055/s-0037-1599225. Epub 2017 Jun 4.

PMID:
28578555
50.

Phylogenetic analysis of emergent Streptococcus pneumoniae serotype 22F causing invasive pneumococcal disease using whole genome sequencing.

Demczuk WHB, Martin I, Hoang L, Van Caeseele P, Lefebvre B, Horsman G, Haldane D, Gubbay J, Ratnam S, German G, Daley Bernier J, Strudwick L, McGeer A, Zhanel GG, Van Domselaar G, Graham M, Mulvey MR.

PLoS One. 2017 May 22;12(5):e0178040. doi: 10.1371/journal.pone.0178040. eCollection 2017.

Supplemental Content

Loading ...
Support Center